Form 4: Eterna Therapeutics Inc. Executive Acquires Stock Options
SEC Form 4 Filing
Sandra M. Gurrola, Sr. VP of Finance at Eterna Therapeutics Inc., reports the acquisition of stock options.
Summary
- Sandra M. Gurrola, the Senior VP of Finance at Eterna Therapeutics Inc., filed a Form 4.
- The form reports the acquisition of 150,000 stock options on February 7, 2025, at an exercise price of $0.34.
- These options vest over time, with one-third vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments.
- Following the transaction, Ms. Gurrola directly owns 150,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, so the sentiment is neutral.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which is important for maintaining investor confidence.
Stakeholder Impact
- The acquisition of stock options by a company executive can be viewed positively by shareholders as it aligns management's interests with theirs.
Key Dates
| Date | Description |
|---|---|
| 02/07/2025 | Date of the stock option transaction. |
| 02/07/2025 | Date the first third of the options begin to vest. |
| 02/10/2025 | Date of the signature on the Form 4. |
| 02/07/2035 | Expiration date of the stock options. |
Keywords
Form 4, Stock Options, Eterna Therapeutics, Insider Trading, Beneficial Ownership, ERNA, Gurrola
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.